Table 1.
In vitro HIV-1 inhibition by covNHR constructs and T20
| Virus | Subtype (coreceptor use) | T20 (nM) | covNHR3 (nM) | covNHR3–ABC (nM) |
| SF162 | B (R5) | 254 ± 364 | 147 ± 4 | 63 ± 43 |
| QH0692 | B (R5) | 1,124 ± 22 | 232 ± 29 | 53 ± 6 |
| KON | CRF02-AG (X4) | 124 ± 16 | 215 ± 57 | 36 ± 11 |
| 92UG024 | C (R5) | 20 ± 3 | 199 ± 86 | 22 ± 3 |
| TV1 | C (R5) | 157 ± 95 | 132 ± 103 | 17 ± 13 |
| 89.6 | B (X4R5) | 45 ± 32 | 247 ± 3 | 87 ± 18 |
| DU174 | C (R5) | 337 ± 159 | 331 ± 143 | 51 ± 3 |
| 92BR025 | C (R5) | 101 ± 48 | 124 ± 35 | 66 ± 29 |
PBMCs were infected using various HIV-1 primary isolates in the presence of the constructs. Values (means ± SDs of three independent experiments) are IC80.